Once upon a time, the Amyloid Cascade Hypothesis
AGEING RESEARCH REVIEWS(2024)
Abstract
Recent trials with monoclonal antibodies targeting amyloid-beta (A beta) in Alzheimer's disease (AD) have sparked a renewed interest in disease-modifying therapies. Despite their promise, these trials leave the issue open and posit some doubts about the validity of the Amyloid Cascade Hypothesis (ACH). While some scores of neurocognitive tests improved upon treatment, real-world clinical benefits were minimal. This Viewpoint discusses additional, often overlooked findings from these trials. We also emphasize the multifactorial nature of AD and the need for a broader research perspective beyond the simplistic disease model provided by the ACH.
MoreTranslated text
Key words
Alzheimer's disease,Dementia,Neurodegeneration,Aducanumab,Lecanemab,Donanemab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined